A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer

Keyphrases

• Phase II Trial 100%
• ER+ Breast Cancer 100%
• HER2-positive 100%
• Dasatinib 100%
• Twice Daily 80%
• HER2+ 60%
• Tumor 40%
• Hormone Receptor-positive 40%
• Human Epidermal Growth Factor Receptor 2 (HER2) 40%
• Metastatic Setting 40%
• Oncogenic Signaling 20%
• Serious Adverse Events 20%
• Chemotherapy 20%
• Treatment Duration 20%
• Drug Toxicity 20%
• Response Rate 20%
• Partial Response 20%
• Endocrine Therapy 20%
• Stable Disease 20%
• Src Kinase 20%
• Pharmacokinetics 20%
• Disease Control Rate 20%
• Targeted Agents 20%
• Gastrointestinal Problems 20%
• Headache 20%
• Response Evaluation Criteria in Solid Tumors (RECIST) 20%
• Pleural Effusion 20%
• Starting Dose 20%
• Asthenia 20%
• Agent Behavior 20%
• Hormone Receptor-positive Advanced Breast Cancer 20%
• Advanced Setting 20%
• Oral Tyrosine Kinase Inhibitors 20%
• Drug-likeness 20%
• Adjuvant Setting 20%
• Common Drugs 20%
• HER2-directed Therapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Hormone Receptor 100%
• Dasatinib 100%
• Diseases 40%
• Adverse Event 20%
• Protein Tyrosine Kinase Inhibitor 20%
• Carcinogenesis 20%
• Chemotherapy Regimens 20%
• Epidermal Growth Factor Receptor 2 20%
• Gamma Urogastrone 20%
• Endocrine Therapy 20%
• Solid Malignant Neoplasm 20%
• Headache 20%
• Gastrointestinal Symptom 20%
• Asthenia 20%
• Pleura Effusion 20%
• Pharmacokinetics 20%